醫渡科技(02158.HK)公佈中期業績 虧損同比收窄19.5% 在新興醫療智能市場收入排名第一
格隆匯11月25日丨醫渡科技(02158.HK)公吿,截至2022年9月30日止六個月,長期疫情肆虐導致收入暫時減少。期間的總收入為人民幣4.74億元,同比下降5.5%,主要是因為若干項目的招標、現場實施及客户驗收延遲。儘管面臨外部壓力,公司仍致力於以戰略聚焦提升盈利能力。
期間虧損減少19.5%至人民幣3.56億元。截至2021年及2022年9月30日止六個月,公司的經調整淨虧損分別為人民幣3.225億元及人民幣2.25億元。
截至2022年9月30日,公司向84家中國頂級研究型醫院以及29個監管機構和政策制定者提供瞭解決方案,並已覆蓋超過1,000家醫院,其中大部分位於中國一線及二線城市。集團服務的生命科學客户數量截至2022年9月30日達到143家。在健康管理平台上至少完成一筆交易的活躍用户數達到15百萬名。
根據弗若斯特沙利文報吿,公司在醫療機構及監管機構醫療智能市場收入排名第一、在新興醫療智能市場收入排名第一,及在整個醫療智能市場收入排名第一。具體而言,公司在新興醫療智能市場佔25.6%的份額。此外,根據弗若斯特沙利文報吿,2030年中國醫療智能行業的市場規模預計將超過人民幣1.1萬億元。
為了實現公司的使命“使價值導向的精準醫療惠及每一個人”,並進一步鞏固公司於醫療智能行業的領先地位,公司將繼續(i)加深和豐富公司對各重點疾病領域的認識和應用;(ii)提升客户價值交付的運營效率;(iii)加強分析驅動研究及人工智能能力,以進一步提升產出效率;(iv)提高客户滲透率及業務分部之間的協同效應;(v)發掘國際市場的機遇;及(vi)通過建立戰略合作伙伴關係、投資和收購進一步豐富公司的生態系統。
公司已經準備好在快速發展的醫療智能領域中成為領導者。公司日後將繼續引入創新型人工智能驅動的應用和解決方案,以把握中國及其他地區的巨大市場機遇,並通過公司的醫療智能基建為生態系統中的行業參與者帶來更多價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.